Dr. Reddy's generic paricalcitol injection launched in US
The Dollar Business Bureau
The Indian pharma and research firm Dr Reddy's Laboratories announced the launch of generic Paricalcitol injection in the US for treatment associated with chronic kidney disease. In a filing with BSE, the company announced the launch of two injections in the 2mcg, 5mcg, and 10mcg range. This product is a generic version of AbbVie Inc’s Zemplar injections added the company in a statement.
"The injection is the first Abbreviated New Drug Application (ANDA) product launched in the US after approval from the US Food and Drug Administration," it said in the statement.
According to IMS Health the Indian pharma major’s Zemplar brand and its generic had US sales of around $22.5 million MAT for the most recent 12 months ending July 2016.
